Dr Reddys Laboratories Ltd
Pharmaceuticals & Biotechnology | Large Cap
Dr. Reddy's Laboratories demonstrates a mixed financial performance. The company shows strong solvency, driven by low debt levels. Growth prospects are also promising, fueled by robust revenue and earnings per share increases. Profitability is a highlight, supported by healthy gross profit and operating margins. However, liquidity appears weak, potentially posing short-term financial challenges. Efficiency is also a concern, with some turnover ratios indicating underutilization of assets. While interest coverage is strong, the absence of equity dividend coverage raises questions about shareholder returns. Overall, Dr. Reddy's exhibits solid long-term potential but needs to address its liquidity and efficiency issues to ensure sustainable growth and stability. The healthcare sector's inherent stability and growing demand for pharmaceuticals provide a favorable backdrop for the company, but effective financial management is crucial to capitalize on these opportunities.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio6.80
- Profitability Ratio7.20
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentStrong
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursNeutral
- 1 DayBearish
- 1 WeekBearish
- 1 MonthBullish
Dr. Reddy's Laboratories demonstrates a mixed financial performance. The company shows strong solvency, driven by low debt levels. Growth prospects are also promising, fueled by robust revenue and earnings per share increases. Profitability is a highlight, supported by healthy gross profit and operating margins. However, liquidity appears weak, potentially posing short-term financial challenges. Efficiency is also a concern, with some turnover ratios indicating underutilization of assets. While interest coverage is strong, the absence of equity dividend coverage raises questions about shareholder returns. Overall, Dr. Reddy's exhibits solid long-term potential but needs to address its liquidity and efficiency issues to ensure sustainable growth and stability. The healthcare sector's inherent stability and growing demand for pharmaceuticals provide a favorable backdrop for the company, but effective financial management is crucial to capitalize on these opportunities.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
32.97
Industry Median
28.62
Large Cap Median
30.25
P/E RATIO
25.31
P/B RATIO
2.80
Industry Median
3.17
Large Cap Median
5.04
P/S RATIO
3.29
Industry Median
3.42
Large Cap Median
5.48
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.94
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1272.1 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤21st Jan 26
Quarterly Financial Results Q3 FY 2025–26
NEUTRAL SENTIMENT
Concall Report⬤24th Oct 25
Q2FY26 Earnings Call
NEUTRAL SENTIMENT
The company exhibits strong growth, driven by robust increases in revenue, operating profit, and earnings per share. This indicates successful expansion and effective management strategies. However, the absence of net income growth is concerning and needs to be addressed to ensure sustainable growth. It also shows the company's ability to be on the top.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 13.11 | 14.5 | 13.54 | 16.54 | 3.23 |
| Operating Profit Growth Rate | -2.74 | 71.71 | 22.61 | 7.74 | -24.49 |
| Earnings Per Share (EPS) Growth | 11.76 | 106.4 | 23.51 | 1.35 | -25.82 |
| Asset Growth Rate | 11.88 | 8.28 | 20.4 | 23.83 | 21.03 |
| Net Income Growth Rate | 11.78 | 106.55 | 23.76 | 2.64 | -27.37 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed picture. Book value and capex are good but Adjusted EPS is not good. Improving adjusted EPS would provide a more comfortable buffer for handling unforeseen expenses or dips in revenue. The financial performance of the company is good but it can be improved in the future.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 25.42 | 55.39 | 66.41 | 68.53 | 49.05 |
| Cash Earnings Per Share (Cash EPS) | 40.33 | 69.36 | 84.92 | 89.51 | 74.01 |
| Book Value Per Share | 231.47 | 280.55 | 340.41 | 404.2 | 451.1 |
| Dividend Per Share (DPS) | 6.03 | 8.12 | 8.02 | 8.13 | 8.04 |
| Capital Expenditures (CapEx) | 1573 | 1879 | 2636 | 3316 | 3669 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios are generally strong, indicating the company's ability to generate profits from its operations. High gross profit and operating margins suggest efficient cost management and pricing strategies. However, the absence of return on equity and net margin is concerning and needs to be addressed to ensure sustainable profitability. It also shows the company's ability to be on the top.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 12.08 | 21.16 | 23.07 | 20.96 | 13.04 |
| Return on Capital Employed (ROCE) | 14 | 27 | 27 | 23 | 14 |
| Return on Equity (ROE) | 11.36 | 19.35 | 19.74 | 17.06 | 10.97 |
| Return on Assets (ROA) | 12.67 | 20.09 | 20.46 | 17.8 | 11.1 |
| Operating Margin | 17.49 | 26.23 | 28.32 | 26.18 | 19.15 |
| Net Margin | 10.13 | 18.27 | 19.91 | 17.54 | 12.34 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios present a mixed picture. While days sales in inventory and receivable days are efficient, the turnover ratios are low. This indicates the company is not effectively utilizing its assets to generate revenue. Improving asset turnover could enhance overall operational efficiency. It also shows the company's scope for improvement.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.65 | 2.68 | 2.69 | 1.79 | 1.53 |
| Inventory Turnover Ratio | 3.93 | 3.91 | 3.84 | 3.83 | 3.97 |
| Receivables Turnover Ratio | 3.7 | 3.54 | 3.67 | 3.82 | 3.52 |
| Days Sales in Inventory Ratio | 92.88 | 93.35 | 95.05 | 95.3 | 91.94 |
| Receivable Days | 98.65 | 103.11 | 99.46 | 95.55 | 103.69 |
| Capital Turnover Ratio | 1.08 | 1.05 | 0.97 | 0.95 | 0.86 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios show a mixed performance. While the interest coverage ratio is strong, indicating a good ability to meet interest obligations, the absence of equity dividend coverage is a significant concern. This suggests that the company is not providing dividends to its shareholders, which may deter investors. This also shows the company's need to improve on dividend policies.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 32.89 | 43.29 | 43.11 | 28.14 | 15.42 |
| Equity Dividend Coverage Ratio | 4.35 | 6.67 | 8.33 | 8.33 | 6.25 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, indicating a solid financial structure and a low risk of financial distress. Low debt ratios suggest a conservative approach to financing, which reduces financial risk. High equity ratios further reinforce financial stability, providing a strong foundation for future growth and investment. This also shows the company's long term stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.03 | 0.01 | 0.03 | 0.03 | 0.04 |
| Debt to Equity Ratio | 0.03 | 0.01 | 0.03 | 0.03 | 0.04 |
| Equity Ratio | 0.97 | 0.99 | 0.97 | 0.97 | 0.96 |
| Debt To Asset Ratio | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, suggesting potential difficulties in meeting its short-term obligations. A low cash ratio indicates limited immediate liquidity, which could be a concern for day-to-day operations. While low liquidity can be a concern but it also can lead to efficient management of resources. Improving current and quick ratios would provide a more comfortable buffer for handling unforeseen expenses or dips in revenue.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.8 | 1.95 | 2.25 | 1.71 | 1.56 |
| Quick Ratio | 1.28 | 1.39 | 1.6 | 1.19 | 1.15 |
| Cash Ratio | 0.25 | 0.2 | 0.18 | 0.18 | 0.18 |
| Operating Cash Flow Ratio | 0.29 | 0.68 | 0.46 | 0.34 | 0.3 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.89 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | Alkem Laboratories Ltd | 8.08 | 27.91 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 4 | Lupin Ltd | 7.84 | 20.16 | Neutral | 8816.00 | 139.25 | 5355.00 |
| 5 | Cipla Ltd | 7.62 | 28.15 | Neutral | 5883.00 | 43.52 | 3862.00 |
| 6 | Mankind Pharma Ltd | 7.61 | 52.10 | Highly Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | Zydus Lifesciences Ltd | 7.60 | 21.38 | Neutral | 8475.00 | 35.38 | 5124.00 |
| 8 | Laurus Labs Ltd | 7.10 | 85.84 | Neutral | 1778.00 | 13.72 | 890.00 |
| 9 | Dr Reddys Laboratories Ltd | 6.49 | 25.31 | Neutral | 6454.00 | 38.58 | 4158.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 45.87 | Neutral | 4572.00 | -7.12 | 1362.00 |
Dr. Reddy's Laboratories showcases proficient management, underscored by consistent financial expansion and effective deployment of capital. The company's steady revenue and profit escalation, bolstered by sound operating profit margins, highlight its operational efficacy. Prudent management of liabilities and a dependable dividend distribution strategy emphasize the management's dedication to fiscal prudence and enriching shareholder value. The confidence of diverse investors, including substantial foreign and domestic institutional participation, further validates the company's strategic path.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (TTM) | 19.89% | Strong revenue expansion |
| Profit Growth (3Y) | 39% | Robust profit growth | |
| ROCE (Current) | 23% | Efficient use of capital | |
| CONS | Promoter Holding | 26.64% | Relatively Low Promoter Holding |
Financial Performance & Growth
Dr. Reddy's Laboratories demonstrates strong and consistent financial performance. The company shows robust sales growth. The operating profit margin (OPM) has been maintained at healthy levels, indicating operational efficiency. Net profit has shown improvement over time, reflecting enhanced profitability.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sales Growth (%) | 6.33% | 0.05% | 11.65% | 14.50% | 13.54% | 16.54% |
| OPM (%) | 23.33% | 18% | 17% | 26% | 28% | 26% |
Capital Efficiency & Returns
Dr. Reddy's Laboratories demonstrates efficient capital utilization and good returns. The current Return on Capital Employed (ROCE) is 23%, indicating that capital is being used productively. Return on Equity (ROE) is also strong, at 19.54%, showing that shareholder funds are yielding good returns.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 22% | 10% | 15% | 27% | 27% | 23% |
| ROE (%) | NA | NA | NA | NA | NA | 19.54 |
Financial Health & Prudence
Dr. Reddy's Laboratories maintains a good level of financial health and prudence. The company's debt management is under control, with borrowings at reasonable levels. It consistently shares profits through dividend payouts, indicating a shareholder-friendly approach.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Debt (₹ Cr) | 4081 | 4609 | 3263 | 1347 | 2002 | 4677 |
| Dividend Payout (%) | 15.67 | 26 | 24.33 | 15 | 12 | 12 |
Shareholding & Ownership Structure
Dr. Reddy's Laboratories has a diversified shareholding structure with moderate promoter holding. The promoter holding is 26.64% as of Mar 2025. Institutional investors (FIIs and DIIs) have significant stakes in the company, indicating investor confidence.
| Metric | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 26.79% | 26.77% | 26.74% | 26.69% | 26.64% |
| FII Holding (%) | 32.40% | 30.93% | 29.03% | 27.25% | 25.75% |
| DII Holding (%) | 10.55% | 14.53% | 14.90% | 23.05% | 25.63% |
Dr. Reddy's Laboratories encounters moderate risk. The volatility in the company's segment performance, influenced by market conditions and regulatory changes, presents a risk. The company's global operations expose it to foreign exchange and interest rate risks, which could impact profitability.
Segment performance volatility
There are fluctuations in quarterly sales and profit growth, indicating some level of volatility in the company's performance.
| Metric | Mar 2022 | Jun 2023 | Sep 2023 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| YOY Sales Growth (%) | 14.82% | 29.14% | 9.01% | 15.81% | 19.89% |
| YOY Profit Growth (%) | -83% | 18% | 33% | 2% | 21% |
Foreign exchange or interest rate exposure
Dr. Reddy's Laboratories, operating globally, is exposed to foreign exchange and interest rate risks. The company's interest expenses have increased over the years.
| Metric | Mar 2014 | Mar 2019 | Mar 2022 | Mar 2025 |
|---|---|---|---|---|
| Interest (₹ Cr) | 127 | 89 | 96 | 283 |
Regulatory compliance cost trends
Expenses have generally increased over the years, which could be partly due to regulatory compliance costs. This trend requires continuous monitoring.
| Metric | Mar 2014 | Mar 2019 | Mar 2022 | Mar 2025 |
|---|---|---|---|---|
| Expenses (₹ Cr) | 10,164 | 12,270 | 17,778 | 24,097 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 101267.29Bullish
- SMA 201266.87Bullish
- SMA 501272.76Bullish
- EMA 101268.27Bullish
- EMA 201268.58Bullish
- EMA 501271.87Bullish
- DEMA 101269.20Bullish
- DEMA 201266.75Bullish
- DEMA 501266.15Bullish
- TEMA 101271.15Bullish
- TEMA 201267.60Bullish
- TEMA 501266.96Bullish
- MACD-1.06Bullish
- ADX20.78Weak Trend
- IndicatorValueSignal
- RSI55.24Neutral
- CCI157.37Overbought
- ROC 90.62Bullish
- ROC 140.28Bullish
- ROC 25-0.28Bearish
- Stoch K51.32Neutral
- Stoch D38.32Neutral
- IndicatorValueSignal
- BB Upper1273.01Neutral
- BB Middle1266.87Neutral
- BB Lower1260.73Neutral
- ATR6.28Low Volatility
- IndicatorValueSignal
- MFI82.47Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101267.88Bullish
- SMA 201271.81Bullish
- SMA 501273.44Bearish
- EMA 101269.36Bullish
- EMA 201270.70Bullish
- EMA 501276.48Bearish
- DEMA 101268.76Bullish
- DEMA 201267.69Bullish
- DEMA 501266.84Bullish
- TEMA 101270.14Bullish
- TEMA 201268.18Bullish
- TEMA 501264.39Bullish
- MACD-2.16Bullish
- ADX18.40Weak Trend
- IndicatorValueSignal
- RSI51.03Neutral
- CCI0.66Neutral
- ROC 90.36Bullish
- ROC 140.11Bullish
- ROC 25-0.39Bearish
- Stoch K46.38Neutral
- Stoch D32.55Neutral
- IndicatorValueSignal
- BB Upper1284.25Neutral
- BB Middle1271.81Neutral
- BB Lower1259.38Neutral
- ATR8.84Low Volatility
- IndicatorValueSignal
- MFI72.02Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101271.61Bullish
- SMA 201273.46Bearish
- SMA 501294.22Bearish
- EMA 101270.90Bullish
- EMA 201274.44Bearish
- EMA 501283.06Bearish
- DEMA 101268.44Bullish
- DEMA 201266.70Bullish
- DEMA 501277.67Bearish
- TEMA 101269.15Bullish
- TEMA 201267.20Bullish
- TEMA 50N/AN/A
- MACD-5.38Bullish
- ADX14.06Weak Trend
- IndicatorValueSignal
- RSI47.53Neutral
- CCI-52.34Neutral
- ROC 9-0.55Bearish
- ROC 140.08Bullish
- ROC 250.80Bullish
- Stoch K26.25Neutral
- Stoch D21.03Neutral
- IndicatorValueSignal
- BB Upper1284.78Neutral
- BB Middle1273.46Neutral
- BB Lower1262.15Neutral
- ATR14.98Low Volatility
- IndicatorValueSignal
- MFI45.89Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101273.22Bearish
- SMA 201284.73Bearish
- SMA 501282.68Bearish
- SMA 1001274.22Bearish
- SMA 2001264.00Bullish
- EMA 101274.77Bearish
- EMA 201280.82Bearish
- EMA 501282.36Bearish
- EMA 1001275.67Bearish
- EMA 2001266.76Bullish
- DEMA 101268.49Bullish
- DEMA 201273.02Bearish
- DEMA 501287.97Bearish
- DEMA 1001287.75Bearish
- DEMA 2001280.66Bearish
- TEMA 101269.45Bullish
- TEMA 201265.34Bullish
- TEMA 501283.52Bearish
- TEMA 1001291.92Bearish
- TEMA 2001282.72Bearish
- MACD-6.39Bearish
- ADX14.74Weak Trend
- IndicatorValueSignal
- RSI45.29Neutral
- CCI-63.10Neutral
- ROC 14-1.42Bearish
- ROC 25-2.42Bearish
- Stoch K34.03Neutral
- Stoch D29.98Neutral
- IndicatorValueSignal
- BB Upper1325.94Neutral
- BB Middle1284.73Neutral
- BB Lower1243.52Neutral
- ATR24.59Low Volatility
- IndicatorValueSignal
- MFI50.05Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 201277.58Bearish
- SMA 501264.43Bullish
- EMA 201280.39Bearish
- EMA 501265.77Bullish
- DEMA 201294.71Bearish
- DEMA 501284.41Bearish
- TEMA 201299.78Bearish
- TEMA 501282.49Bearish
- MACD10.82Bullish
- ADX11.35Weak Trend
- IndicatorValueSignal
- RSI50.60Neutral
- CCI35.08Neutral
- ROC 14-2.18Bearish
- ROC 25-0.22Bearish
- Stoch K56.72Neutral
- Stoch D63.23Neutral
- IndicatorValueSignal
- BB Upper1353.77Neutral
- BB Middle1277.58Neutral
- BB Lower1201.38Neutral
- ATR64.99Low Volatility
- IndicatorValueSignal
- MFI55.74Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 61276.18Bullish
- SMA 121262.58Bullish
- SMA 241263.18Bullish
- EMA 61281.80Bullish
- EMA 121265.45Bullish
- EMA 241235.50Bullish
- DEMA 61301.70Bullish
- DEMA 121288.58Bullish
- DEMA 241305.84Bearish
- TEMA 61309.90Bearish
- TEMA 121290.85Bullish
- TEMA 241283.51Bullish
- MACD108.76Bearish
- ADX9.93Weak Trend
- IndicatorValueSignal
- RSI56.29Neutral
- CCI75.33Neutral
- ROC 255.05Bullish
- ROC 5051.73Bullish
- Stoch K58.90Neutral
- Stoch D61.74Neutral
- IndicatorValueSignal
- BB Upper1366.77Neutral
- BB Middle1246.45Neutral
- BB Lower1126.14Neutral
- ATR126.08Low Volatility
- IndicatorValueSignal
- MFI63.65Neutral